Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta : extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution Read More >

10/19/2021 | 01:11pm EST

Media release

Medacta extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution

CASTEL SAN PIETRO, 19 October 2021 - Medacta announces the release of MyKnee(R) R, the newest addition to its MySolutions(R) Personalized Ecosystem. MyKnee R is the unique-on-the-market patient-specific set of 3D-printed blocks that can be directly positioned on the failed primary implant in situ, in order to easily proceed with its replacement. Starting from a CT scan, MySolutions engineers create a 3D reconstruction of the patient's joint where a failed primary implant has been positioned. This reconstruction is then used to accurately plan the positioning of a new prosthesis, chosen from Medacta's portfolio of total knee replacement solutions, ranging from a minimum level of constraint (GMK(R) Sphere and GMK(R) Primary) to semi- and fully constrained solutions (GMK(R) Revision and GMK(R) Hinge). MyKnee R is the game-changing technology to facilitate the introduction to total knee revision surgeries, where even highly experienced surgeons are often confronted with complex and time-consuming cases.

Regarding this aspect, Dr. Vicente Leon, the first surgeon to use the system at the Hospital Clínico Universitario Virgen de La Arrixaca (Murcia, Spain), says: 'There is nothing better than being able to rely on a patient-specific solution for each kind of knee surgery. Medacta has more than ten years of experience in patient-specific solutions, and I think that the MyKnee R is a great addition to this range of options. Thanks to the 3D preoperative planning tool and the possibility of accurately and quickly replicating the planning during the surgery with the 3D-printed guides, every surgeon can easily achieve conservative bone cuts, none or minimal alteration of the joint line and an optimized alignment of revision implant components, also when revising failed total knee implants.'

MyKnee R is part of Medacta's MySolutions ecosystem of personalized medicine products and technologies. Originally introduced as MyKnee(R) to address an unmet need for better implant positioning in the total knee replacement market, MySolutions can now also be used in hip (MyHip(R), MyHip(R) Planner, MyHip(R) Verifier), shoulder (MyShoulder(R)) and spine (MySpine(R)) procedures. In addition to patient-matched surgical guides, MySolutions also includes advanced planning and verification tools, augmented reality-based personalized execution, patient pathway optimization and clinical data collection and analysis.

Dr. Leon concludes 'Medacta has a solution for each specific patient's need, providing a comprehensive implant portfolio that covers unicompartmental knee arthroplasties, with the GMK(R) UNI and MOTO(R) partial knee systems, total knee arthroplasties, with the medially-stabilized GMK(R) Sphere, and also total knee revisions, with the GMK Revision System. These implants are also available with the SensiTiNTM ceramic-like coating, which offers a hypoallergenic alternative by reducing the release of metal ions into the patient's body. Now, with MyKnee R, also the MySolutions portfolio is complete, and every kind of knee surgery can be managed using Medacta's patient-specific guides.'

MyKnee R is also supported by a tailored educational offering. With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on total knee revision techniques and products with personalized high-level educational pathways, supporting surgeons with focused activities as they master revision. With Medacta the surgeon is never alone.

Discover more about MyKnee R and Medacta's knee portfolio.

Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60

About Medacta
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.


Medacta Group SA published this content on 19 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 October 2021 17:10:03 UTC.

ę Publicnow 2021
All news about MEDACTA GROUP SA
01/20Medacta FY21 Revenue Up 20% on Carryover, Customer Acquisition
01/20MEDACTA : 2021 Full Year Unaudited Top-Line Figures Presentation
01/20Medacta Group SA reports strong revenue growth of 21.4% in 2021
01/17MEDACTA : Company Presentation
01/14MEDACTA : and the M.O.R.E Institute celebrate significant milestones
2021Medacta Launches 360░ (Anterior and Posterior) Cervical Platform, Highlighting MySpine ..
2021Medacta Launches 360░ (Anterior and Posterior) Cervical Platform, Highlighting MySpine ..
2021German Prosecutors Drop Proceedings on Medacta
2021MEDACTA GROUP SA : German public prosecutor discontinues proceedings against Medacta and M..
2021Medacta marks its GMK Sphere 10-year anniversary
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Sales 2021 365 M 414 M 414 M
Net income 2021 58,2 M 66,0 M 66,0 M
Net Debt 2021 75,6 M 85,7 M 85,7 M
P/E ratio 2021 40,1x
Yield 2021 0,63%
Capitalization 2 320 M 2 630 M 2 631 M
EV / Sales 2021 6,56x
EV / Sales 2022 5,75x
Nbr of Employees 1 246
Free-Float -
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Last Close Price 116,00 €
Average target price 132,07 €
Spread / Average Target 13,9%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-15.49%2 630
MEDTRONIC PLC2.57%141 985